Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.46 |
| ▸ | NMBR | P28336 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050539 | 0.88 | SIRT2 (0.49) | SIRT2NMBR | |
| SCHEMBL2053305 | 0.86 | SIRT2 (0.45) | SIRT2NMBR | |
| SCHEMBL2180673 | 0.85 | SIRT2 (0.45) | SIRT2NMBR | |
| SCHEMBL2002061 | 0.78 | SIRT2 (0.45) | SIRT2NMBRKDM4E | |
| SCHEMBL28803224 | 0.77 | SIRT2 (0.49) | SIRT2NMBRKDM4E | |
| SCHEMBL19208762 | 0.76 | SIRT2 (0.51) | SIRT2NMBR | |
| Acetic Acid SCHEMBL7659782 | 0.75 | SIRT2 (0.47) | SIRT2NMBR | |
| SCHEMBL31370665 | 0.75 | SIRT2 (0.48) | SIRT2NMBR | |
| SCHEMBL877052 | 0.74 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL1038850 | 0.74 | SIRT2 (0.52) | SIRT2NMBRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| CN-116710469-A | Linear Apelin receptor agonists | 赫帕雷斯治疗有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022079428-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| EP-3000482-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2021-04-21 | — | — | EP | disclosed |
| EP-3000482-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2021-04-21 | — | — | EP | disclosed |
| CN-104311657-B | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-111560060-A | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-104327182-B | Double acylated GLP-1 derivatives | 诺沃—诺迪斯克有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| EP-2513141-A2 | GLP-1 ANALOGUES AND DERIVATIVES | Novo Nordisk A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| EP-2512518-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | Novo Nordisk A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011080102-A2 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080102-A2 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | US | disclosed |
| WO-2011080103-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | US | disclosed |
| WO-2011080103-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011073328-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NOVO NORDISK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073328-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NOVO NORDISK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166321-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, IAPP, GCG | SIRT2 527/4885NMBR 3828/4885RIPK1 1256/4885 |
| US-20230382949-A1 | LINEAR APELIN RECEPTOR AGONISTS | APLNR, MTNR1A, EDNRA | SIRT2 4152/4885NMBR 387/4885RIPK1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.